Cosmo Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 3/6
Cosmo Pharmaceuticals is a dividend paying company with a current yield of 3.81% that is well covered by earnings. Next payment date is on 6th June, 2025 with an ex-dividend date of 4th June, 2025.
Key information
3.8%
Dividend yield
0.3%
Buyback Yield
| Total Shareholder Yield | 4.1% |
| Future Dividend Yield | 0% |
| Dividend Growth | 2.0% |
| Next dividend pay date | 06 Jun 25 |
| Ex dividend date | 04 Jun 25 |
| Dividend per share | n/a |
| Payout ratio | 25% |
Recent dividend and buyback updates
Recent updates
Clascoterone Trials Completion And AI Expansion Will Open Future Markets
Mar 17 Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings.Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity
Jan 23
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Jan 20Revenue: €265.7 million, representing a 186% year-over-year increase from €92.8 million in 2023. This includes €185 million in non-recurring revenues from Medtronic linked to the December 2023 expandeCosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
Nov 22Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
May 02Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Dec 01Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 29We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Mar 31Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: COPN has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: COPN's dividend payments have increased, but the company has only paid a dividend for 9 years.
Dividend Yield vs Market
| Cosmo Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (COPN) | 3.8% |
| Market Bottom 25% (CH) | 1.9% |
| Market Top 25% (CH) | 4.0% |
| Industry Average (Pharmaceuticals) | 3.4% |
| Analyst forecast (COPN) (up to 3 years) | 0% |
Notable Dividend: COPN's dividend (3.81%) is higher than the bottom 25% of dividend payers in the Swiss market (1.9%).
High Dividend: COPN's dividend (3.81%) is low compared to the top 25% of dividend payers in the Swiss market (3.98%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (25.2%), COPN's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (20.9%), COPN's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 00:52 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo Pharmaceuticals N.V. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |
| Laura Hindley | Berenberg |